NCX 470 shows positive IOP reduction in phase 2 trial
SAN FRANCISCO — NCX 470, Nicox’s novel second-generation nitric oxide-donating bimatoprost analog, showed superior IOP lowering compared with latanoprost in a phase 2 clinical trial, according to a speaker here.
The multicenter Dolomites trial compared NCX 470 0.065% with latanoprost for diurnal IOP reduction. Those treated with NCX 470 experienced a mean diurnal IOP reduction between 7.6 mm Hg and 9.8 mm Hg compared with a reduction of 6.3 mm Hg to 8.8 mm Hg in the latanoprost group, Tomas Navratil, PhD, Nicox executive vice president and head of research and development, said during his presentation at Glaucoma 360: New Horizons Forum.
“More importantly, NCX 470 also demonstrated statistical superiority in unmatched IOP lowering at 8 a.m., 10 a.m. and 4 p.m. vs. latanoprost,” he said. “The range of IOP lowering, 7.6 mm Hg to 9.8 mm Hg, to our knowledge, is the most robust IOP lowering ever demonstrated by an eye drop in a clinical trial.”
No drug-related serious adverse events or evidence of treatment-related systemic events were reported in the trial, and only three of 433 participants discontinued treatment due to an adverse event.
“We believe this new molecular treatment has the potential to be the best first-line IOP-lowering therapy for glaucoma patients worldwide for the next 20 to 30 years,” Navratil told Healio/OSN. – by Rebecca L. Forand
Navratil T. Nicox Glaucoma 360 presentation. Presented at: Glaucoma 360: New Horizons Forum; Feb. 7, 2020; San Francisco.
Disclosure: Navratil reports he is an employee of Nicox.